美国旧金山延长分析性治疗中断的组合 HIV 治愈相关试验中的参与者体验。
Participant experiences in a combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States.
机构信息
Division of Infectious Diseases and Global Public Health (IDGPH), Department of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.
Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
出版信息
HIV Res Clin Pract. 2024 Jan 29;25(1):2312318. Epub 2024 Feb 13.
BACKGROUND
There is limited systematic information available about the perspectives of participants enrolled in intensive combination HIV cure-related trials inclusive of an extended analytical treatment interruption (ATI).
OBJECTIVE
To assess and understand experiences of people with HIV involved in a combination HIV cure-related trial with an extended ATI.
METHODS
The trial included five interventions and was followed by an ATI lasting up to 52 wk. From 2022 - 2023, we conducted in-depth interviews with study participants following their extended ATIs. Interviews were audio-recorded, transcribed, and analyzed conventional thematic analysis.
RESULTS
We interviewed seven participants. The majority were male, White, and non-Hispanic, with a median age of 37 years. Trust in the research team, scientific altruism and hope of becoming a post-intervention controller were key motivators for joining the trial. Interviewees reported being satisfied with their decision to participate in the trial and the extended ATI. Most recounted feelings of worry related to viral rebound during the ATI. Participants reported both defeat and relief with ART restart. Four faced challenges with protecting partners from HIV during their ATI, such as trying to find out if their partner(s) were using pre-exposure prophylaxis.
CONCLUSIONS
Our findings demonstrate potential improvements for future ATI trial participant experiences, such as more robust resources for psychosocial support and partner protections. Dedicating greater effort to understanding participant ATI experiences can inform the design of future participant-centered HIV cure trial protocols.
背景
目前关于参加包括延长分析性治疗中断(ATI)在内的强化组合 HIV 治愈相关试验的参与者的观点,系统性信息有限。
目的
评估和了解参与组合 HIV 治愈相关试验并进行延长 ATI 的 HIV 感染者的体验。
方法
该试验包括五项干预措施,随后进行长达 52 周的 ATI。从 2022 年至 2023 年,我们在参与者完成延长 ATI 后对其进行了深入访谈。访谈内容进行了录音、转录和分析,采用常规主题分析方法。
结果
我们共采访了 7 名参与者。他们大多数是男性、白人、非西班牙裔,中位年龄为 37 岁。对研究团队的信任、科学利他主义和成为干预后控制器的希望是他们加入试验的主要动机。受访者表示对参与试验和延长 ATI 的决定感到满意。大多数人都对 ATI 期间病毒反弹感到担忧。参与者在重新开始接受抗逆转录病毒治疗时,既感到沮丧又感到宽慰。有 4 人在 ATI 期间面临着保护伴侣免受 HIV 感染的挑战,例如试图了解他们的伴侣是否使用了暴露前预防措施。
结论
我们的研究结果表明,未来 ATI 试验参与者的体验可以得到改善,例如提供更强大的心理支持和伴侣保护资源。投入更多精力了解参与者的 ATI 体验,可以为未来以参与者为中心的 HIV 治愈试验方案的设计提供信息。
相似文献
引用本文的文献
本文引用的文献
Lancet Infect Dis. 2023-10
J Acquir Immune Defic Syndr. 2022-3-1